diatrazoate meglumine (Renografin) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety. A commonly used x-ray contrast medium. Used, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium. Radiopaque agents are drugs used to help diagnose certain medical problems. They contain iodine, which blocks x-rays. Depending on how the radiopaque agent is given, it localizes or builds up in certain areas of the body. The resulting high level of iodine allows the x-rays to make a "picture" of the area. The areas of the body in which the radiopaque agent localizes will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral, Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$2.7430 - $10.8875
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2,4,6-triiodo-3,5-diacetamidobenzoic acid | 3,5-bis(acetylamino)-2,4,6-triiodobenzoic acid | 3,5-diacetamido-2,4,6-triiodobenzoic acid | acide amidotrizoique | acidum amidotrizoicum | acidum diacetylaminotrijodbenzoicum | amidotrizoate | amidotrizoic acid | amidotrizoic acid (anhydrous) | amidotrizoic acid methylglucamine salt | angiografin | angiovist 282 | cardiografin | cystografin | cystografin dilute | diatrazoate | diatrizoate | diatrizoate meglumine | diatrizoate methylglucamine | diatrizoate sodium | diatrizoesaure | diatrizoic acid | diatrizoic acid (anhydrous) | diatrizoic acid dihydrate | diiodomethanesulfonic acid, disodium salt | hypaque | hypaque | hypaque-cysto | hypaque sodium | md | md-50 | meglumine amidotrizoate | meglumine amidotrizoate injection | meglumine diatrizoate | meglumine sodium amidotrizoate injection | methalamic acid | methylglucamine diatrizoate | reno | reno-30 | reno-60 | reno-dip | renografin | sodium amidotrizoate | sodium diatrizoate | triombrin | urografin acid | urogranoic acid | urothrast | urotrast | urovist cysto | urovist cysto pediatric | urovist meglumine diu/ct | urovist sodium | urovist sodium 300

Organizations (14)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (2)


 

Gastrointestinal Diseases (approved 1958)

Urinary Bladder Diseases (approved 1955)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Abdominal Injuries (Phase 3)

Colorectal Neoplasms (Phase 4)

Healthy Volunteers (Phase 4)

Intestinal Diseases (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue